Tiziana’s Intranasal Foralumab Trial Hits New Milestone

Tiziana Life Sciences has reached a key milestone in its Phase 2a clinical trial of intranasal Foralumab for non‑active secondary progressive multiple sclerosis (na‑SPMS). Patient dosing has now commenced at Yale’s Multiple Sclerosis Center, expanding the study’s reach beyond its initial sites and underscoring progress in the multicentre, randomized, double‑blind, placebo‑controlled investigation.

Launched in late 2023, the trial explores two dosing regimens of Foralumab against placebo, assessing effects on microglial activation via PET imaging, alongside standard measures of disability, cognition, fatigue, and quality of life. The inclusion of Yale adds to a network of major US research centres (including Johns Hopkins, UMass, Brigham and Women’s Hospital, and more) enhancing the study’s robustness.

This advancement highlights Tiziana’s commitment to evaluating this novel, non‑systemic immune therapy in a patient population with significant unmet need. The trial remains on schedule for topline data by year‑end, with an open‑label extension planned to assess longer‑term safety and efficacy.